Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2011

01.08.2011 | Original Article

Idiopathic Noncirrhotic Intrahepatic Portal Hypertension is Associated with Sustained ADAMTS13 Deficiency

verfasst von: Ian Mackie, C. E. Eapen, Desley Neil, Andrew S. Lawrie, Andrew Chitolie, Jean C. Shaw, Elwyn Elias

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

ADAMTS13 deficiency leading to excess ultralarge von Willebrand factor (VWF) multimers and platelet clumping is typically found in thrombotic thrombocytopenic purpura (a type of thrombotic microangiopathy). Idiopathic noncirrhotic intrahepatic portal hypertension (NCIPH) is a microangiopathy of portal venules associated with significant thrombocytopenia and predisposing gut disorders.

Aim

To determine whether the portal microangiopathy in NCIPH is associated with ADAMTS13 deficiency.

Methods

Plasma levels of ADAMTS13, anti-ADAMTS13 antibodies, and VWF were compared between cases (NCIPH patients) and controls (with chronic liver diseases of other etiology) matched for severity of liver dysfunction. Eighteen NCIPH patients [median (range) MELD score 12 (7–25)] and 25 controls [MELD score 11 (4–26)] were studied.

Results

ADAMTS13 activity was reduced in all 18 NCIPH patients and significantly lower than controls (median, IQR: 12.5%, 5–25% and 59.0%, 44–84%, respectively, P < 0.0001) [normal range for plasma ADAMTS13 activity (55–160%)]. ADAMTS13 activity was <5% in 5/18 NCIPH patients (28%) and 0/25 controls (P = 0.009). ADAMTS13 antigen levels were also decreased. Sustained low ADAMTS13 levels were seen in four NCIPH patients over 6 weeks to 11 months (highest ADAMTS13 level in each patient: <5%, 6%, 6%, and 25%), despite two patients having MELD score 12. Although nine cases had low titer anti-ADAMTS13 antibodies, there was no significant difference between cases and controls. Abnormally large VWF multimers were observed in 4/11 NCIPH patients (36%) and in 0/22 controls (P = 0.008).

Conclusions

Sustained deficiency of ADAMTS13 appears characteristic of NCIPH, irrespective of severity of liver disease.
Literatur
1.
Zurück zum Zitat Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;6:627–634.CrossRef Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;6:627–634.CrossRef
2.
Zurück zum Zitat Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;2:275–280.CrossRef Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;2:275–280.CrossRef
3.
Zurück zum Zitat Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. Gastroenterol Hepatol. 2002;5:526–534. Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. Gastroenterol Hepatol. 2002;5:526–534.
4.
Zurück zum Zitat Henderson JM. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;6:610–611.CrossRef Henderson JM. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;6:610–611.CrossRef
5.
Zurück zum Zitat Madhu K, Ramakrishna B, Zachariah U, Eapen CE, Kurian G. Non-cirrhotic intrahepatic portal hypertension. Gut. 2008;57:1529.PubMedCrossRef Madhu K, Ramakrishna B, Zachariah U, Eapen CE, Kurian G. Non-cirrhotic intrahepatic portal hypertension. Gut. 2008;57:1529.PubMedCrossRef
6.
Zurück zum Zitat Boyer JL, Hales MR, Klatskin G. “Idiopathic” portal hypertension due to occlusion of intrahepatic portal veins by organized thrombi. A study based on postmortem vinylite-injection corrosion and dissection of the intrahepatic vasculature in 4 cases. Medicine (Baltimore). 1974;1:77–91. Boyer JL, Hales MR, Klatskin G. “Idiopathic” portal hypertension due to occlusion of intrahepatic portal veins by organized thrombi. A study based on postmortem vinylite-injection corrosion and dissection of the intrahepatic vasculature in 4 cases. Medicine (Baltimore). 1974;1:77–91.
7.
Zurück zum Zitat Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore). 1980;5:367–379. Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore). 1980;5:367–379.
8.
Zurück zum Zitat Kingham JG, Levison DA, Stansfeld AG, Dawson AMl. Non-cirrhotic intrahepatic portal hypertension: a long term follow-up study. Q J Med. 1981;199:259–268. Kingham JG, Levison DA, Stansfeld AG, Dawson AMl. Non-cirrhotic intrahepatic portal hypertension: a long term follow-up study. Q J Med. 1981;199:259–268.
9.
Zurück zum Zitat Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology. 1996;3:195–204.CrossRef Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology. 1996;3:195–204.CrossRef
11.
Zurück zum Zitat Scully M, Yarranton H, Liesner R, et al. Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819–826.PubMedCrossRef Scully M, Yarranton H, Liesner R, et al. Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819–826.PubMedCrossRef
12.
Zurück zum Zitat Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106:922–924.PubMedCrossRef Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106:922–924.PubMedCrossRef
13.
Zurück zum Zitat Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005;85:780–788.PubMedCrossRef Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005;85:780–788.PubMedCrossRef
14.
Zurück zum Zitat Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31:11–19.PubMedCrossRef Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31:11–19.PubMedCrossRef
15.
Zurück zum Zitat Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115:2752–2761.PubMedCrossRef Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115:2752–2761.PubMedCrossRef
16.
Zurück zum Zitat Eapen CE, Nightingale P, Hubscher SG, et al. Non cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci. 2011;56:227–235.PubMedCrossRef Eapen CE, Nightingale P, Hubscher SG, et al. Non cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci. 2011;56:227–235.PubMedCrossRef
17.
Zurück zum Zitat Austin A, Campbell E, Lane P, Elias E. Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody. Gut. 2004;7:1032–1034.CrossRef Austin A, Campbell E, Lane P, Elias E. Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody. Gut. 2004;7:1032–1034.CrossRef
18.
Zurück zum Zitat Manavalan JS, Hernandez L, Shah JG, et al. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010;71:50–57.PubMedCrossRef Manavalan JS, Hernandez L, Shah JG, et al. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010;71:50–57.PubMedCrossRef
19.
Zurück zum Zitat Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100–106.PubMedCrossRef Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100–106.PubMedCrossRef
20.
Zurück zum Zitat Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 2008;6:1233–1235.PubMedCrossRef Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 2008;6:1233–1235.PubMedCrossRef
21.
Zurück zum Zitat Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019–1029.PubMed Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019–1029.PubMed
22.
Zurück zum Zitat Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386–1389.PubMed Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386–1389.PubMed
23.
Zurück zum Zitat Yarranton H, Lawrie AS, Mackie IJ, Pinkoski L, Corash L, Machin SJ. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion. 2005;45:1453–1458.PubMedCrossRef Yarranton H, Lawrie AS, Mackie IJ, Pinkoski L, Corash L, Machin SJ. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion. 2005;45:1453–1458.PubMedCrossRef
24.
Zurück zum Zitat Brown JE, Bosak JO. An Elisa test for the binding of von Willebrand antigen to collagen. Thromb Res. 1986;43:303–311.PubMedCrossRef Brown JE, Bosak JO. An Elisa test for the binding of von Willebrand antigen to collagen. Thromb Res. 1986;43:303–311.PubMedCrossRef
25.
Zurück zum Zitat Lawrie AS, Hoser MJ, Savidge GF. Phast assessment of vWf:Ag multimeric distribution. Thromb Res. 1990;59:369–373.PubMedCrossRef Lawrie AS, Hoser MJ, Savidge GF. Phast assessment of vWf:Ag multimeric distribution. Thromb Res. 1990;59:369–373.PubMedCrossRef
26.
Zurück zum Zitat Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–2735.PubMedCrossRef Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–2735.PubMedCrossRef
27.
Zurück zum Zitat Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61.PubMedCrossRef Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61.PubMedCrossRef
28.
Zurück zum Zitat Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007;138:534–540.PubMedCrossRef Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007;138:534–540.PubMedCrossRef
29.
Zurück zum Zitat Madhu K, Avinash B, Ramakrishna B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol. 2009;28:83–87.PubMedCrossRef Madhu K, Avinash B, Ramakrishna B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol. 2009;28:83–87.PubMedCrossRef
30.
31.
Zurück zum Zitat Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631–640.PubMedCrossRef Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631–640.PubMedCrossRef
32.
Zurück zum Zitat Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–1511.CrossRef Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–1511.CrossRef
33.
Zurück zum Zitat Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost. 2007;5:866–867.PubMedCrossRef Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost. 2007;5:866–867.PubMedCrossRef
34.
Zurück zum Zitat Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood. 2006;107:118–125.PubMedCrossRef Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood. 2006;107:118–125.PubMedCrossRef
35.
Zurück zum Zitat Brill A, Fuchs T, Yang J, et al. VWF-mediated platelet adhesion is required for deep vein thrombosis in a flow restriction model. Blood 2009; 114: abstract 473. Brill A, Fuchs T, Yang J, et al. VWF-mediated platelet adhesion is required for deep vein thrombosis in a flow restriction model. Blood 2009; 114: abstract 473.
36.
Zurück zum Zitat Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008;205:2065–2074.PubMedCrossRef Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008;205:2065–2074.PubMedCrossRef
37.
Zurück zum Zitat Sarin SK, Kumar A, Chawla YK, et al. (APASL consensus) Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007;1:398–413.PubMedCrossRef Sarin SK, Kumar A, Chawla YK, et al. (APASL consensus) Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007;1:398–413.PubMedCrossRef
38.
Zurück zum Zitat Crawley JT, De Groot R, Luken BM. Circulating ADAMTS-13-von Willebrand factor complexes: an enzyme on demand. J Thromb Haemost. 2009;7:2085–2087.PubMedCrossRef Crawley JT, De Groot R, Luken BM. Circulating ADAMTS-13-von Willebrand factor complexes: an enzyme on demand. J Thromb Haemost. 2009;7:2085–2087.PubMedCrossRef
39.
Zurück zum Zitat Ricketts LM, Dlugosz M, Luther KB, Haltiwanger RS, Majerus EM. O-fucosylation is required for ADAMTS13 secretion. J Biol Chem. 2007;282:17014–17023.PubMedCrossRef Ricketts LM, Dlugosz M, Luther KB, Haltiwanger RS, Majerus EM. O-fucosylation is required for ADAMTS13 secretion. J Biol Chem. 2007;282:17014–17023.PubMedCrossRef
40.
Zurück zum Zitat Zhou W, Tsai H-M. N-glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood. 2009;113:929–935.PubMedCrossRef Zhou W, Tsai H-M. N-glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood. 2009;113:929–935.PubMedCrossRef
41.
Zurück zum Zitat McKinnon TA, Chion ACK, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111:3042–3049.PubMedCrossRef McKinnon TA, Chion ACK, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111:3042–3049.PubMedCrossRef
42.
Zurück zum Zitat Blomme B, van Steenkiste C, Callewaert N, van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol. 2009;50:592–603.PubMedCrossRef Blomme B, van Steenkiste C, Callewaert N, van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol. 2009;50:592–603.PubMedCrossRef
43.
Zurück zum Zitat Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;5:1238–1247. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;5:1238–1247.
Metadaten
Titel
Idiopathic Noncirrhotic Intrahepatic Portal Hypertension is Associated with Sustained ADAMTS13 Deficiency
verfasst von
Ian Mackie
C. E. Eapen
Desley Neil
Andrew S. Lawrie
Andrew Chitolie
Jean C. Shaw
Elwyn Elias
Publikationsdatum
01.08.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1729-4

Weitere Artikel der Ausgabe 8/2011

Digestive Diseases and Sciences 8/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.